{"filing":{"accession_number":"0001437749-26-032960","cik":"0001822791","ticker":"CLNN","company_name":"Clene Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-15","primary_document":"clnn20261012_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926032960/clnn20261012_8k.htm"},"events":[{"id":36206,"run_id":33372,"accession_number":"0001437749-26-032960","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"Clene Inc. entered into a subaward amendment on October 15, 2026 for the fourth year of a $45.1 million NIH Grant, securing $7.2 million for the period September 1, 2026 to August 31, 2027 to support an Expanded Access Program for CNM-Au8® treatment of ALS. This is a material operational/strategic event involving continuation of a significant government research grant that supports the company's clinical program, but it does not fit the specific categories of M\u0026A, debt issuance, equity issuance, or other defined event types—it is a material research funding agreement continuation.","company_name":"Clene Inc.","ticker":"CLNN","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40533,"accession_number":"0001437749-26-032960","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Clene Inc. entered into a subaward amendment on October 15, 2026 for the fourth year of a $45.1 million NIH Grant, securing $7.2 million for the period September 1, 2026 to August 31, 2027 to support an Expanded Access Program for CNM-Au8® treatment of ALS. This is a material operational/strategic event involving continuation of a significant government research grant that supports the company's clinical program, but it does not fit the specific categories of M\u0026A, debt issuance, equity issuance, or other defined event types—it is a material research funding agreement continuation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:03:56.085603+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40533,"accession_number":"0001437749-26-032960","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Clene Inc. entered into a subaward amendment on October 15, 2026 for the fourth year of a $45.1 million NIH Grant, securing $7.2 million for the period September 1, 2026 to August 31, 2027 to support an Expanded Access Program for CNM-Au8® treatment of ALS. This is a material operational/strategic event involving continuation of a significant government research grant that supports the company's clinical program, but it does not fit the specific categories of M\u0026A, debt issuance, equity issuance, or other defined event types—it is a material research funding agreement continuation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:03:56.085603+00:00","company_name":"Clene Inc.","ticker":"CLNN","filing_date":"2026-10-19"}]}